Mentions
Extended reach
Total likes
Video views
AI synopsis
The responses highlight key results, like 82% of patients achieving effective hemostasis, and praise the drug’s FDA approval, reflecting a positive reception and perceived significance of the research. The tone, emphasizing efficacy and safety, demonstrates active engagement with its potential clinical impact.
Most discussions highlight positive outcomes from the study, emphasizing successful hemostasis and the potential benefits of Andexanet Alfa.
The posts reflect moderate interest, focusing on specific findings like the 82% success rate and the drug being FDA-approved, indicating engagement with the clinical significance.
Participants reference the study details, such as the rapid reversal of anticoagulant effects and the mention of clinical outcomes, showing thoughtful engagement.
The discussions suggest that the findings could influence clinical practice, especially with terms like 'good/excellent hemostasis' and noting the drug’s approval, indicating a perceived high impact.
#Research Letter: Andexanet alfa treatment in patients with acute gastrointestinal bleeding with Factor Xa inhibitor demonstrate rapid reversal of FXai anticoagulant effect and clinical hemostasis. @DebSiegal https://t.co/P7fJBoRy93
16) In a subanalysis of the #ANNEXA_4trial, 82% of pts presenting with major #GIB experienced good/excellent #hemostasis after treatment with #andexanet_alfa, the only @US_FDA-approved specific #reversal agent for #FXa inhibitors. See
RT @CircAHA: #Research Letter: Andexanet alfa treatment in patients with acute gastrointestinal bleeding with Factor Xa inhibitor demonstra…
RT @CircAHA: #Research Letter: Andexanet alfa treatment in patients with acute gastrointestinal bleeding with Factor Xa inhibitor demonstra…
RT @CircAHA: #Research Letter: Andexanet alfa treatment in patients with acute gastrointestinal bleeding with Factor Xa inhibitor demonstra…
RT @CircAHA: #Research Letter: Andexanet alfa treatment in patients with acute gastrointestinal bleeding with Factor Xa inhibitor demonstra…
Dr Deborah Siegal discusses the recent paper on the efficacy and safety of Andexanet Alfa for patients with acute gastrointestinal bleeding on Factor Xa inhibitors, highlighting key findings from the ANNEXA4 subanalysis…
Dr. Deborah Siegal discusses the recent ANNEXA-4 subanalysis on the efficacy and safety of Andexanet Alfa for patients with acute gastrointestinal bleeding on Factor Xa inhibitors. She highlights treatment challenges…
16) In a subanalysis of the #ANNEXA_4trial, 82% of pts presenting with major #GIB experienced good/excellent #hemostasis after treatment with #andexanet_alfa, the only @US_FDA-approved specific #reversal agent for #FXa inhibitors. See
RT @CircAHA: #Research Letter: Andexanet alfa treatment in patients with acute gastrointestinal bleeding with Factor Xa inhibitor demonstra…
RT @CircAHA: #Research Letter: Andexanet alfa treatment in patients with acute gastrointestinal bleeding with Factor Xa inhibitor demonstra…
RT @CircAHA: #Research Letter: Andexanet alfa treatment in patients with acute gastrointestinal bleeding with Factor Xa inhibitor demonstra…
RT @CircAHA: #Research Letter: Andexanet alfa treatment in patients with acute gastrointestinal bleeding with Factor Xa inhibitor demonstra…
RT @CircAHA: #Research Letter: Andexanet alfa treatment in patients with acute gastrointestinal bleeding with Factor Xa inhibitor demonstra…
RT @CircAHA: #Research Letter: Andexanet alfa treatment in patients with acute gastrointestinal bleeding with Factor Xa inhibitor demonstra…
RT @CircAHA: #Research Letter: Andexanet alfa treatment in patients with acute gastrointestinal bleeding with Factor Xa inhibitor demonstra…
#Research Letter: Andexanet alfa treatment in patients with acute gastrointestinal bleeding with Factor Xa inhibitor demonstrate rapid reversal of FXai anticoagulant effect and clinical hemostasis. @DebSiegal https://t.co/P7fJBoRy93